This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock KOOL vs. THMO, LUCD, OBIO, KYTX, GNLX, ATOS, TARA, CCCC, PROC, and LUNGShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Lucid Diagnostics (LUCD), Orchestra BioMed (OBIO), Kyverna Therapeutics (KYTX), Genelux (GNLX), Atossa Genetics (ATOS), Protara Therapeutics (TARA), C4 Therapeutics (CCCC), Procaps Group (PROC), and Pulmonx (LUNG). These companies are all part of the "medical" sector. Cesca Therapeutics vs. Its Competitors ThermoGenesis Lucid Diagnostics Orchestra BioMed Kyverna Therapeutics Genelux Atossa Genetics Protara Therapeutics C4 Therapeutics Procaps Group Pulmonx Cesca Therapeutics (NASDAQ:KOOL) and ThermoGenesis (NASDAQ:THMO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has more volatility and risk, KOOL or THMO? Cesca Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, ThermoGenesis has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Do institutionals and insiders believe in KOOL or THMO? 3.1% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 5.8% of ThermoGenesis shares are held by institutional investors. 68.9% of Cesca Therapeutics shares are held by company insiders. Comparatively, 78.0% of ThermoGenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to KOOL or THMO? In the previous week, Cesca Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score. Company Overall Sentiment Cesca Therapeutics Neutral ThermoGenesis Neutral Which has higher valuation and earnings, KOOL or THMO? ThermoGenesis has lower revenue, but higher earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCesca Therapeutics$9.67M2.95-$39.72M-$3.60-3.28ThermoGenesis$9.61M0.00-$17.98M-$5.14N/A Is KOOL or THMO more profitable? ThermoGenesis has a net margin of 0.00% compared to Cesca Therapeutics' net margin of -98.84%. ThermoGenesis' return on equity of 0.00% beat Cesca Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cesca Therapeutics-98.84% -77.30% -37.75% ThermoGenesis N/A N/A N/A SummaryThermoGenesis beats Cesca Therapeutics on 8 of the 10 factors compared between the two stocks. Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.56M$105.01M$5.60B$9.11BDividend Yield0.50%N/A5.24%4.02%P/E Ratio-3.285.8327.9620.25Price / Sales2.950.48430.5799.61Price / CashN/A45.3037.4658.16Price / Book3.802.708.045.49Net Income-$39.72M$18.75M$3.18B$250.27M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$11.82-0.5%N/A+11.4%$28.56M$9.67M-3.2853THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040LUCDLucid Diagnostics2.6167 of 5 stars$1.06+1.9%$3.55+234.9%+33.2%$112.52M$4.35M-0.7970News CoverageOBIOOrchestra BioMed2.9528 of 5 stars$2.93+1.4%$14.20+384.6%-63.4%$110.72M$2.64M-1.654News CoverageKYTXKyverna Therapeutics2.5011 of 5 stars$2.82+10.6%$18.50+556.0%-58.1%$110.21M$7.03M-0.8396News CoverageGNLXGenelux1.2667 of 5 stars$3.48+20.0%$17.75+410.1%+34.5%$109.43M$10K-3.9510News CoverageAnalyst UpgradeHigh Trading VolumeATOSAtossa Genetics2.8879 of 5 stars$0.85+0.2%$6.17+627.9%-26.7%$109.25MN/A-4.038TARAProtara Therapeutics1.9166 of 5 stars$3.03+8.2%$20.50+576.6%+30.3%$108.03MN/A-1.7630Positive NewsCCCCC4 Therapeutics3.0375 of 5 stars$1.71+12.5%$12.00+601.8%-56.4%$107.93M$35.58M-1.16150Positive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-62.2%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeLUNGPulmonx3.587 of 5 stars$2.73+3.4%$11.53+322.2%-59.9%$106.28M$83.79M-1.90250 Related Companies and Tools Related Companies THMO Alternatives LUCD Alternatives OBIO Alternatives KYTX Alternatives GNLX Alternatives ATOS Alternatives TARA Alternatives CCCC Alternatives PROC Alternatives LUNG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOOL) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
